Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.

@article{Jayne2000IntravenousIF,
  title={Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.},
  author={David Jayne and Helen Chapel and Dwomoa Adu and Siraj Misbah and Donal O'Donoghue and Deborah Leilaru Scott and Christina M Lockwood},
  journal={QJM : monthly journal of the Association of Physicians},
  year={2000},
  volume={93 7},
  pages={433-9}
}
Intravenous immunoglobulin (IVIg) is a potential alternative treatment for anti-neutrophil cytoplasm antibody (ANCA)-associated systemic vasculitis (AASV) with less toxicity than conventional immunosuppressive agents. This randomized, placebo-controlled trial aimed to investigate the efficacy of a single course of IVIg (total dose 2 g/kg) in previously-treated AASV with persistent disease activity in whom there was an intention to escalate therapy. Vasculitic activity was monitored by the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 130 extracted citations

Similar Papers

Loading similar papers…